Cloverna
Latest round
- Series A
Last raised
- Aug 2022
Total raised
- $0.7M
Investors
- 1
About Cloverna
Based in Kurashiki, Japan, and founded in 2022 by its CEO Tatsuo Ito and co-founder Yurika Shimizu, Cloverna Inc. operates as a research and development company for pharmaceuticals that utilize RNA-targeted drug discovery technology. In August 2022, Cloverna Inc. As of September 2022, the company by its CEO Tatsuo Ito. Cloverna Inc. offers RNA targeted drug discovery platform that extracts RNA motif sequences to serve as drug discovery targets from a large number of candidates.), and diseases caused by the accumulation of abnormal proteins such as amyotrophic lateral sclerosis (ALS) and dilated cardiomyopathy (DCM).
Who invested in Cloverna
1 investor across 1 round
See all investors in Cloverna
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 30, 2022
Amount
$0.7M
Investors
Questions about Cloverna
Who invested in Cloverna?
Cloverna has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cloverna raised?
Cloverna has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cloverna last raise money?
Cloverna's most recent round on record is a Series A, in Aug 2022.
What does Cloverna do?
Based in Kurashiki, Japan, and founded in 2022 by its CEO Tatsuo Ito and co-founder Yurika Shimizu, Cloverna Inc.
Where is Cloverna headquartered?
Cloverna is headquartered in Kurashiki, Japan.
Which VCs invest in companies like Cloverna?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Cloverna's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Cloverna? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.